Gain Therapeutics Stock (NASDAQ: GANX) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 10.00 / 354.21K |
Day Range | - - - |
52 Wk Range | 0.89 - 5.33 |
Market Cap | $37.03M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 60 |
Short Interest | 2.28% |
Days to Cover | 1 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Gain Therapeutics (NASDAQ:GANX) through any online brokerage.
Other companies in Gain Therapeutics’s space includes: Kezar Life Sciences (NASDAQ:KZR), Fortress Biotech (NASDAQ:FBIO), Estrella Immunopharma (NASDAQ:ESLA), Acurx Pharmaceuticals (NASDAQ:ACXP) and OncoCyte (NASDAQ:OCX).
Gain Therapeutics has a consensus price target of $8.00.
The stock price for Gain Therapeutics (NASDAQ: GANX) is $1.45 last updated September 19, 2024 at 7:38 PM EDT.
There are no upcoming dividends for Gain Therapeutics.
Gain Therapeutics’s Q3 earnings are confirmed for Tuesday, November 12, 2024.
There is no upcoming split for Gain Therapeutics.
Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.